The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Thank you Emerald, that all makes sense regarding various possible outcomes, but just disappointing that the time lines have slipped. However, I have confidence that they will get it right and hopefully this could lead to a game changer for diagnostic albeit time delayed through a Solaris lab.
Unfortunately a lack of trust based on history, over promising, under delivery and now perceived lack of control. Also concerns about potential covenant breaks, if they don’t hit targets, Hopefully this is a big kick up the proverbial snd they focus on delivery.
If so, I agree, undervalued.
Thank you 404.
I note from today’s RNS that Q2 23 produced 14.9k sales at circa 20% less selling price, so I estimate the revenue was 1.8m. Obviously licensing money/deals are presumably taken as revenue and cash (when received)
In order Not to breach lending covenant requirements, what revenue/prescriptions do we need to achieve in Q1? As far as I can see from info available, it looks like around 30-34k prescriptions required. Can any concur or offer a number?
Be careful here guys. This is likely being pushed for the next raise as this company is running it’s cash thank on empty. I have seen this before with Xbio and they WILL need cash imminently. If you catch the wave right and jump off before the break, then you may well make a few bob. I am a LTH in deep water waiting and hoping for a turnaround, but it will take some time and Money! GLA
Well stated Tomo.
Angle have an excellent product but in a complicated and multi use market. Contracts are won via , market awareness, trial, results, advertising, referrals and hard work. They don’t come like selling sweets. based on the nature of the market, it cannot be easy to make cash flow projections to which the directors would be accountable. I.e. damned if you do damned if you don’t. Clearly They are trying to build a profitable and very successful business, which could help millions of people, but this is likely to be a long journey. In 2008, I invested in a pharmaceutical company called Verona Pharma (VRP) and At one stage, I thought I was going to lose all of my investment. The company had one main product with one main market. 13 years later, I finally was rewarded for my patience, albeit overextended. My investment was diluted on many occasions, but I always believed in the product. Patience is Required!
BUT solid progress must be demonstrated by the company and in this case, we are slowly seeing it.
Hopefully bigger players will see this and invest.
There are very good reasons for the very low price, recovery and re-trace, which I am sure you are well aware of. Patience will be rewarded. Next catalyst will be news on the existing tailings dam raise and permission for the new one, followed by resumption of use of agitation plant.